

# Paraherquamide J: A Novel Prenylated Indole Alkaloid from *Penicillium janthinellum* HK1-6 as a Potential Therapeutic Agent Against ESKAPE Pathogens


Dear Editor,

Paraherquamide J, a prenylated indole alkaloid derived from the marine fungus *Penicillium janthinellum* HK1-6 (Zheng et al., 2020), holds significant promise as a novel antimicrobial agent against ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). These multidrug-resistant (MDR) pathogens are responsible for severe nosocomial infections and pose a major challenge to global healthcare due to their ability to evade conventional antibiotics (Sousa et al., 2021). Paraherquamide J's unique structural features, including its indole alkaloid core and prenyl modifications, suggest potential interactions with bacterial membranes, efflux pumps, and essential enzymatic pathways, making it a strong candidate for combating antimicrobial resistance (AMR).

The primary mechanism of Paraherquamide J against ESKAPE pathogens may involve disruption of bacterial cell membrane integrity, leading to leakage of intracellular components and cell death (Figure 1). Additionally, it could inhibit essential bacterial enzymes, such as DNA gyrase and topoisomerase IV, which are crucial for DNA replication and

bacterial survival. Paraherquamide J may also function as a quorum-sensing inhibitor, preventing biofilm formation, a key defense mechanism of ESKAPE bacteria that enhances antibiotic resistance. Its ability to bypass traditional antibiotic resistance mechanisms, such as  $\beta$ -lactamase production and efflux pump overexpression, further enhances its therapeutic potential.

Future applications of Paraherquamide J could include its development as a standalone antimicrobial agent or in combination with existing antibiotics to restore their efficacy against resistant strains. Its integration into nanoparticle-based drug delivery systems may improve its stability and targeted delivery, reducing toxicity and enhancing therapeutic outcomes. Moreover, structural modifications through medicinal chemistry approaches could optimize its potency, pharmacokinetics, and spectrum of activity. Clinical trials will be essential to assess its safety, efficacy, and potential resistance development. If successfully developed, Paraherquamide J could serve as a groundbreaking marine-derived antibiotic, offering a much-needed solution against MDR ESKAPE pathogens and helping to curb the rising global threat of antibiotic resistance.



**Figure 1:** Different ways of Paraherquamide J on targeting ESKAPE Pathogens.

© The Author(s). 2025 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

**Declarations****Ethics approval statement**

No ethical approval was required for the current study as it did not deal with any human or animal samples.

**Consent to participate**

Not applicable

**Consent to publish**

Not applicable

**Data Availability Statement**

The data are available from the corresponding author upon reasonable request

**Competing Interests**

The authors declare that they have no conflict of interest

**Funding**

Not Applicable

**Acknowledgements**

Not Applicable

**Author contribution**

S.B: Conceptualization, Writing and Reviewing draft, Investigation, Project administration, and Supervision

**Reference**

1. Sousa, S.A., Feliciano, J.R., Pita, T., Soeiro, C.F., Mendes, B.L., Alves, L.G., Leitão, J.H., 2021. Bacterial Nosocomial Infections: Multidrug Resistance as a Trigger for the Development of Novel Antimicrobials. *Antibiotics* 10, 942. <https://doi.org/10.3390/antibiotics10080942>
2. Zheng, Y.-Y., Shen, N.-X., Liang, Z.-Y., Shen, L., Chen, M., Wang, C.-Y., 2020. Paraherquamide J, a new prenylated indole alkaloid from the marine-derived fungus *Penicillium janthinellum* HK1-6. *Nat. Prod. Res.* 34, 378–384. <https://doi.org/10.1080/14786419.2018.1534105>

**\*Corresponding Author:** Subalakshmi V

School of Chemical and Biotechnology, Shanmugha Arts, Science, Technology & Research Academy, Thirumalaisamudram-613401, Thanjavur, Tamil Nadu, India

Email: [velusubi1245@gmail.com](mailto:velusubi1245@gmail.com)

**Articleinfo**

**Received:** 25 August 2024

**Revised:** 14 December 2024

**Accepted:** 25 December 2024

**Published:** 3 January 2025

**How to cite this article:** Subalakshmi V. (2025). Paraherquamide J: A Novel Prenylated Indole Alkaloid from *Penicillium janthinellum* HK1-6 as a Potential Therapeutic Agent Against ESKAPE Pathogens 2(1), 3-4.

<https://doi.org/10.26524/amr.2025.1.2>